Recursion Pharmaceuticals is trading at $3.49 (-10.05%) amid a sharp risk-off session, with broad technology losses as investors react to fears of tighter AI regulation and slower data-center development. - Biotech ETF XBI is down 5.19%. - Available reports show no clear company-specific catalyst for the November 5 decline; a director’s disclosed share sale followed a prearranged trading plan. - The November 2 earnings report is recent but does not explain today’s drop.